10 On October 24, at the European Society for Medical Oncology (ESMO) congress in Madrid, Merck and Moderna presented the results of a phase 3 trial with a therapeutic mRNA vaccine (remember the one for Covid?) made to measure for each of the patients who received it. The clinical trial, named INTerpath-001, has been conducted on people who underwent surgery for high-risk melanoma.

]]>